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STUDY PROTOCOL Open Access
Cognitive Bias Modification for paranoia
(CBM-pa): study protocol for a randomised
controlled trial
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Abstract
Background: Persecutory delusions are the most common type of delusions in psychosis and present in around
10–15% of the general population. Persecutory delusions are thought to be sustained by biased cognitive and emotional
processes. Recent advances favour targeted interventions, focussing on specific symptoms or mechanisms. Our aim is to
test the clinical feasibility of a novel psychological intervention, which manipulates biased interpretations toward more
adaptive processing, in order to reduce paranoia in patients.
Methods: The ‘Cognitive Bias Modification for paranoia’ (CBM-pa) study is a feasibility, double-blind, randomised
controlled trial (RCT) for 60 stabilised outpatients with persistent, distressing paranoid symptoms. Patients will
be randomised at a 50:50 ratio, to computerised CBM-pa or a text-reading control intervention, receiving one
40-min session per week, for 6 weeks. CBM-pa involves participants reading stories on a computer screen,
completing missing words and answering questions about each story in a way that encourages more helpful
beliefs about themselves and others. Treatment as Usual will continue for patients in both groups. Patients will be
assessed by a researcher blind to allocation, at baseline, each interim session, post treatment and 1- and 3-
month follow-up post treatment. The primary outcome is the feasibility parameters (trial design, recruitment
rate and acceptability) of the intervention. The secondary outcomes are clinical symptoms (including severity
of paranoia) as assessed by a clinical psychologist, and ‘on-line’ measurement of interpretation bias and stress/distress.
The trial is funded by the NHS National Institute for Health Research.
Discussion: This pilot study will test whether CBM-pa has the potential to be a cost-effective, accessible and
flexible treatment. If the trial proves feasible and demonstrates preliminary evidence of efficacy, a fully powered
RCT will be warranted.
Trial registration: Current Controlled Trials ISRCTN: 90749868. Retrospectively registered on 12 May 2016.
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Background
Psychosis is one of the most disabling mental health
conditions, with a lifetime rate of 3.5% [1], and it is asso-
ciated with significant distress, unemployment, impaired
social functioning, physical ill health and suicidal idea-
tion [2]. Persecutory delusions are the most frequent
and clinically significant symptoms of psychosis. They
are associated with considerably more distress than
other types of delusion [3]; are most likely to be acted
upon [4] and represent a strong predictor of hospitalisa-
tion [5]. Over one third of all UK psychiatric patients
suffer from persecutory delusions, and they are reported
in depression [6], bipolar disorder [7], posttraumatic
stress disorder [8], anxiety [9], and with the highest
prevalence and greatest intensity in schizophrenia [10].
A significant proportion of patients suffering from perse-
cutory delusions, continue to experience distressing
symptoms despite available treatments [11, 12].
Previous research showed that the distribution of para-
noid thinking in the general population is continuous,
ranging from social evaluative concerns (e.g. fears of re-
jection) to severe threat (e.g. people trying to cause sig-
nificant harm), indicating a hierarchical structure to
paranoia [13–17]. Persecutory delusions are the extreme
point on the continuum of paranoid belief, and are likely
to be perpetuated by biased cognitive-emotional pro-
cesses [13–18].
‘Cognitive bias’ refers to selective processing of infor-
mation matching the core content of the pathology of a
disorder; for example, individuals with threat-related
persecutory delusions interpret emotionally ambiguous
information as threatening. Savulich et al. [17] point out
that ‘cognitive deficits are impairments in cognitive func-
tioning at the global level, whereas cognitive biases in-
volve the selective processing of pathology-congruent
information with the potential to confirm matching
pathological beliefs’ (p. 516).
For example, general problems in attentional function-
ing or working memory are cognitive deficits, but repeat-
edly attending to a certain type of maladaptive stimulus,
in preference to more benign alternatives, or consistently
interpreting emotionally ambiguous information in one
(maladaptive) direction would both be examples of a cog-
nitive bias (in attention and interpretation, respectively).
Furthermore, recent theoretical thinking in psychosis is
attempting to integrate cognitive models of threat ap-
praisals with models based on neural findings in areas
such as the amygdala, the insula, the hippocampus, the
anterior cingulate cortex and the prefrontal cortex [19].
These cognitive biases help to cause and maintain a
range of psychopathologies [20, 21], including psychosis/
delusions [3]. Cognitive therapy can work by changing
underlying biases so that these maintaining mechanisms
are no longer present and, ideally, patients instead acquire
biases that promote wellbeing [22, 23] and, as a result,
symptoms resolve. However, the Schizophrenia Commis-
sion report that the NICE-recommended psychological
therapy for psychosis, cognitive behavioural therapy
(CBT), is received by only 1 in 10 of those who could
benefit and has shown only moderate effect sizes for delu-
sions [24, 25]. New directions in treatments for delusions
emphasise briefer, targeted interventions, with a focus on
putative causal factors, such as cognitive biases [26, 27].
Here, we aim to test the feasibility of a new targeted
psychological intervention ‘Cognitive Bias Modification
for paranoia’ (CBM-pa) which uses a computerised task
to manipulate biased interpretations of emotionally am-
biguous information, with the aim of promoting more
adaptive processing. CBM is a validated, theory-driven
treatment with an established methodology [28]. CBM
has arisen directly from laboratory research into the na-
ture of the cognitive biases across a range of disorders.
Two high-impact articles have alerted the research com-
munity to CBM’s potential as a novel treatment [29, 30],
with evidence of its efficacy in reducing pathological be-
liefs, symptoms and stress vulnerability in anxiety and
depression [31]. More cautionary reports have also
pointed out that efficacy varies across studies [32] and
researchers need to proceed with caution in applying
CBM to new clinical populations, ensuring that the ne-
cessary basic research has been conducted prior to
implementing CBM methodologies.
The first necessary step in this basic research is to iden-
tify the relevant naturally occurring biases and how they
present in the target disorder. The CBM methodology can
then be adapted to be specifically relevant for that target
disorder. Previous studies suggest that a negative inter-
pretation bias occurs in those with elevated vulnerability
to paranoia, and that this bias may be strongest for ma-
terial matching paranoid beliefs both in nonclinical and
clinical samples [17, 18]. Specifically, interpretation of
everyday information as personally threatening has been
found to be related to the onset and maintenance of para-
noid symptoms [33]. Therefore, an intervention targeting
these biases offers potential to reduce distressing paranoia.
Moritz and colleagues [34], have pioneered ‘metacognitive
training’ (MCT) for a range of social-cognitive biases
found in psychosis. Using group training, they obtained
improvements in delusions in a large randomised con-
trolled trial (RCT). Previous studies, using computerised
treatment targeting reasoning bias in patients with perse-
cutory delusions, also demonstrated the effectiveness of a
brief reasoning intervention in improving both reasoning
processes and paranoia [35, 36].
However, the use of CBM to modify interpretations of
material specifically relevant to paranoia and paranoid
beliefs remains unexplored and CBM-pa was designed to
fill this gap.
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Feasibility, double-blind randomised controlled trial
The current study is a feasibility, double-blind RCT of
CBM-pa with patients who suffer from persistent, distres-
sing paranoid symptoms. The CBM-pa intervention is de-
livered on a computer, set up by the researchers and,
thereafter, is a self-directed, automated package, self-
administered by the patient. The intervention uses am-
biguous scenarios which could potentially be interpreted
in a manner that reinforces paranoia, or instead could be
interpreted in more benign way. While patients read these
scenarios they are asked to complete experimental tasks
(word completion and comprehension questions) which
implicitly influence the interpretation that is actually
made. Additional file 1: Figures S1a–h shows an example
trial from the intervention. The intervention aims to re-
duce paranoid beliefs, paranoid symptoms and stress/dis-
tress, and will be evaluated in comparison to a text-
reading control (see Additional file 1: Figure S1i). Both
conditions will be conducted in addition to Treatment
as Usual (TAU) which will be in the form of individua-
lised combinations of medication and care coordin-
ation. This design directly evaluates the hypothesised
‘active ingredient’ (bias reduction) by using the control
condition to match all other aspects of the adjunct
intervention.
The main objective of this feasibility study is to test
the integrity of the protocol in terms of length and feasi-
bility. A secondary objective is a preliminary evaluation
of efficacy. For this the primary outcome is the severity
of paranoid symptoms. A third objective is the selection
of primary outcomes (e.g. paranoid symptoms, interpret-
ation bias and vulnerability to stress) for the subsequent
trial based on consensus after presentation of results to
the Steering Group. This decision will be informed by
(1) observed effect sizes and (2) opinions on the most
important outcome from qualitative interviews. The ne-
cessary withholding of information about group assign-
ment might be a significant issue because heightened
suspiciousness is an inherent feature of clinical paranoia.
Estimates of population variances of the main out-
comes for future power calculations will be based on
Browne [37], who suggests using the upper 80th per-
centile of confidence intervals around the estimates.
Methods
The study has been approved by the London – City Road
and Hampstead Research Ethics Committee on 26 Febru-
ary 2016 (reference: 16/LO/0071) and has been registered
(Current Controlled Trials, ID: ISRCTN90749868).
Amendments will be submitted to both the Ethics Com-
mittee and the Clinical Trials Register. Informed consent
will be obtained from all participants. A Trial Steering
Group (TSG) and LEAP (Lived Experience Advisory
Panel) have been formed. The TSG also functions as a
Data Monitoring Committee by assessing, at regular inter-
vals, the progress of the study, participant safety, feedback
and complaints, study milestones and, if relevant issues
arise, whether to continue, modify, or stop the trial.
Participants and study setting
The primary endpoints of this feasibility trial are factors
that affect successful trial conduct, rather than measures
of intervention effects. Hence, power analyses for inter-
vention outcomes were not undertaken in advance. The
study recruitment target is 60 participants, consistent with
the widely accepted sample size of 20–40 participants for
pilot studies [38, 39], allowing for some dropout. Assum-
ing a follow-up rate of 70% or more, a one-sided 95% con-
fidence interval for this key feasibility parameter will
extend no more than 10% from the observed proportion.
A minimum sample size of 30 is sufficient to obtain robust
estimates of population variances for future power calcula-
tions [37, 38]. Therefore, recruiting 60 patients in this
pilot trial should be sufficient to provide estimates of
population variance on key outcomes.
Participants will be recruited from a range of local
sources, including: Institute of Psychiatry, Psychology
and Neuroscience (IoPPN) and South London and
Maudsley (SLaM) research registers; SLaM NHS Foun-
dation Trust services; service users’ networks and volun-
tary sector organisations. Patients will be screened and
selected for invitation to participate by researchers ac-
cording to the inclusion and exclusion criteria. The in-
clusion criteria are:
1. Any diagnosis featuring clinically significant
persecutory or paranoid symptoms, present for at
least the preceding month. In order to be included
in the study, participants had to score 3 or more on
the Positive And Negative Syndrome Scale (PANSS)
item 6 [40] of the positive symptoms scale and
which measures ‘suspiciousness/persecution’.
Paranoid symptoms were assessed over the
telephone by a trained researcher. A score of 3
reflects ‘mild’ paranoid symptoms as expressed by ‘a
guarded or even openly distrustful attitude’;
2. Displaying a baseline interpretation bias. A link is
sent to potential participants to complete a bias
screening task online (or, for those without Internet
access, participants are asked to come to the IoPPN
and complete it using local laptops). The bias
screening task is a shortened (eight-item) version of
the Similarity Rating Task (SRT) [41] delivered using
the on-line data collection software Qualtrics.
Shortened versions have demonstrated adequate
reliability in previous work [42]. The items used in
this task were sourced by randomly selecting from
the original CBM-pa training items used in sessions
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1, 2 or 3. It was ensured that the items chosen
were distinctive, and had an even number of yes/no
correct responses. In the screening SRT, sentences
reflecting non-paranoid (i.e. benign) and paranoid
interpretations were denoted T+ and T−, respectively,
and rated by participants on a 1–4 Likert scale (higher
score = stronger endorsement). An interpretation
bias screening score is calculated: T+ minus
T−. Screening bias scores, therefore, range from
+3 to −3 with positive and negative scores reflecting
bias favouring nonparanoid and paranoid meanings,
respectively. A bias score of 1 or below during the SRT
at screening is necessary to be selected for the study.
This cutoff has been adopted in order to exclude
anyone showing a strong positive interpretation
bias. The screening version of the SRT differed
slightly from the baseline version, in that there
were only eight SRT items and no foils
3. Stable on all prescribed medication (including anti-
psychotic) for at least the last 3 months and expected
to be so for study duration
4. Age range of 18–65 years
5. Capacity to consent defined as the ability to use and
understand information to make a decision, and
communicate any decision made. This is assessed by
a trained research assistant (CM) and a clinical
psychologist (AT) according to the Mental Capacity
Act [43]
Exclusion criteria are:
1. Severe cognitive impairment, or illiteracy
2. Major physical illness (cancer, heart disease, stroke)
3. Major substance or alcohol misuse, and
4. Currently receiving, or soon due to receive, a
psychological therapy targeting the same
psychological mechanisms as CBM-pa (paranoid
beliefs), or having done so in the last 3 months
Psychological therapy is defined as five or more con-
secutive sessions with a trained therapist, either in an in-
dividual or group setting, for the purpose of alleviating
symptoms arising from paranoia or related issues. Re-
ceipt of therapy for any other purpose (e.g. occupational
or art therapy; counselling) will be assessed on a case-
by-case basis, against the principle that eligibility re-
quires any cognitive mechanisms targeted by therapy to
be independent of those targeted by CBM-pa.
Randomisation and blinding
We will conduct this study following Consolidated Stan-
dards of Reporting Trials (CONSORT) guidelines [44].
The King’s Clinical Trials Unit will conduct double-blind
randomisation. CBM-pa is self-administered, allowing
researchers to be blind to condition. Control and inter-
vention are designed to appear procedurally identical.
Blinding will be implemented by the creation of 60
unique, randomly labelled computer programmes which
mask the assigned treatment arm from researchers.
Should occasional instances of unblinding accidentally
occur, these can be reported without jeopardising the sta-
tus of the remainder of the sample. Participants and re-
searchers will be asked to guess the assigned condition to
evaluate the success of double-blinding at the end of all
data collection. Adaptive randomisation by minimisation
will be used that allocates subjects to the treatment group
that best maintains balance in stratifying factors, such as:
gender, severity of baseline paranoia measured by the
PANSS item 6 [40], severity of interpretation bias mea-
sured by the SRT [41].
Interventions
Participants will attend the Institute of Psychiatry,
Psychology and Neuroscience, King’s College London, or
the NIHR/Wellcome Trust King’s Clinical Research Fa-
cility, for six sessions and receive postal/telephone 1-and
3-month follow-ups (respectively at 4 and 12 weeks from
end of last session). See Fig. 1 for the trial flow diagram.
Groups should be equalised on the expectation of bene-
fit because the introduction to each trial arm is delivered
by computer and standardised across the two conditions.
Expectation of benefit will be assessed using the Credibil-
ity and Expectancy Questionnaire [45]. The intervention
will be delivered on laboratory-owned laptops.
Qualitative interviews (n = 8) will be conducted after the
end of quantitative data collection, providing an in-depth
assessment of participants experience of the intervention,
including potential side effects (e.g. unexpected emer-
gence, rather than amelioration of paranoid thoughts).
Treatment-as-Usual (TAU) + CBM-pa
We will record details of TAU received during the study
period using a standardised template to record partici-
pants’ responses to a series of set questions about treat-
ment received, including pharmacotherapy and any
treatment changes. The first 10 participants consenting
for access to notes will be used to assess feasibility of
case-note data collection to record TAU.
CBM-pa procedure and item development
CBM-pa (see Additional file 1: Figures S1a-h) consists of
40 unique training items completed per session (dur-
ation 40 min plus midpoint break), for six weekly ses-
sions, involving a total of 240 different items.
To maximise clinical relevance, the LEAP group devel-
oped over 100 examples of everyday situations drawn from
their real experiences to be used as content for the six study
intervention sessions. Training items were selected from
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these and further developed by the research team into the
format required for use as a training item (see example
given in Additional file 1). The items were arranged into six
topic areas/categories of paranoia, namely:
1. Physical harm (37 items): e.g. being poisoned,
injured, threatened by terrorism, killed, etc.
2. Social/interpersonal threat (87 items): e.g. being
gossiped about, judged, disliked, dumped, fired
3. Medical/paramedical/health care threat (19 items):
e.g. being prescribed drugs with adverse effects,
being conspired against by medical staff conspire
against you, having one’s deoxyribonucleic acid
(DNA) stolen
4. Threat of persecution/spying (40 items): e.g. being
stalked, spied on, followed, arrested by police
5. Delusions of reference/magical thinking (15 items):
e.g. interpreting stimuli as personal messages
6. General suspiciousness/distrust not relating to
physical threat or persecution (42 items): e.g. being
robbed, plagiarised, irritated by neighbours
Items were independently rated, according to their se-
verity, by two clinical psychologists (EP, AT). The intra-
class correlation coefficient for the severity ratings (ICC)
was 0.992 (indicative of strong inter-rater reliability).
Training items were distributed across sessions in terms
of their mean severity ratings such that items become
more severe from one session to the next, based on previ-
ous research findings suggesting this is more acceptable to
participants with pre-existing negative biases [42].
A typical item is shown in Additional file 1: Figure S1b.
Each item depicts an emotionally ambiguous situation, is
interactive and involves participants reading three lines of
text on a computer screen, then completing a missing
word and answering a related question (yes/no). Both the
word completion and the question encourage participants
to interpret the ambiguity inherent in the situation in a
manner that promotes helpful beliefs about them-
selves and others (see example given in Additional file 1:
Figures S1a − h). Equal numbers of ‘yes’ and ‘no’ question
responses are presented randomly to avoid participants
developing a fixed response set. Word completions were
unique (no repetitions) and constructed by removing all
vowels, then reinstating one in cases where LEAP feed-
back indicated that the resulting difficulty level was too
high. In response to further feedback from LEAP a
‘clue’ was created for each item by adding more letters
to encourage the participant to try again following an
incorrect response.
Fig. 1 Trial flow diagram
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In order to reflect the increasing drill down towards core
beliefs that is used in traditional cognitive therapies, ses-
sions 1 and 2 are delivered using the word ‘thoughts’ (e.g.
‘You fly to a business meeting abroad. You plan to attend
the guest reception but arrive 20 min late. Upon entering
the reception you look around and think everyone looks…’);
3 and 4 using ‘assumptions’ (e.g. ‘You are running late for
an appointment and rush to get to the bus stop on time. As
you approach, gesturing for the bus to wait, you see the
driver look in the mirror and pull away, smiling. You as-
sume that the bus driver just…’) and 5 and 6 using ‘beliefs’
(e.g. ‘You are sitting at a bus stop when a group of teen-
agers walk over and light up their cigarettes. As you cough
loudly, they throw the empty carton saying ‘smoking kills’
towards you and laugh. You believe that this is…’).
Treatment-as-usual (TAU) + text-reading control
A computerised text-reading control will be given to
those randomised to this condition (see Additional file 1:
Figure S1i). The experience is identical to CBM-pa, but
content omits the active ingredient: resolution of an
emotionally ambiguous situation in a benign/non-para-
noid manner. Instead control participants read and re-
spond to factual material. Similarly to CBM-pa, training
items were divided into six sessions of 40 items each. It
was ensured that there are no obvious systematic differ-
ences between the control and intervention items (equal
number of yes/no answers in each session, no word rep-
etitions in the incomplete words, each item is three
sentences long over three lines, topics are evenly distrib-
uted between each session).
The LEAP group reviewed all items to be used in the
study intervention and control arm for readability and
suitability and tested the software to be used in the study
for acceptability.
Outcome measures and timeline
The Standard Protocol Items: Recommendations for
Interventional Trials (SPIRIT) diagram provides an over-
view of the measures used in the trial and their time
points (see Fig. 2). To evaluate the optimum number of
sessions, dose-response effects will be assessed by meas-
uring paranoid symptoms and interpretation bias at each
session (i.e. what ‘dose’ of interpretation bias training
achieves the best reduction in paranoia) using the sec-
ondary outcome measures (see below). This will inform
decisions about number of sessions for full trial.
Primary outcomes
As the study is a feasibility evaluation of the CBM-pa inter-
vention there is no single primary outcome measure. In-
stead, feasibility will be assessed on the basis of rates of
recruitment, consent, dropout and follow-up. In addition,
acceptability of randomisation will be examined, including
the integrity of double-blinding. Qualitative interviews will
be conducted after the end of quantitative data collection,
using a purposively selected subsample of eight active-arm
patients. Purposive selection will represent sample variation
Fig. 2 Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) diagram
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in the following priority order: gender, severity of paranoia,
severity of bias, age and ethnicity. The aim is to explore ac-
ceptability, barriers to participation, promoting engagement
and optimum form of delivery of the intervention.
Secondary outcomes
The study will sample three domains of possible out-
comes: interpretation bias, clinical symptoms and stress/
distress. For each we will collect information on (1)
comprehensibility and suitability and (2) variance esti-
mates by calculating standardised treatment effect sizes
(Cohen’s d) and their confidence intervals.
Interpretation bias will be measured using the:
 Similarity Rating Task (SRT) [41]. This is a standard
test used to measure interpretation bias. Items
describe ambiguous social scenarios that permit either
paranoid- or non-paranoid interpretations and were
developed by Savulich et al. [17], based on Freeman
and Garety’s [46] definition of paranoia as a person’s
belief that intentional ‘harm is occurring, or is going to
occur’. Items are shown to have sensitivity to detect
differences between high-paranoid and low-paranoid
groups of participants who were found to differ in their
interpretation bias on paranoid item content [17], such
that the high-paranoid group showed a significantly
more maladaptive pattern of interpretation (reduced
endorsement of positive and non-paranoid interpreta-
tions) compared with the low-paranoid group
For the ‘encoding’ part of the task participants read 12
ambiguous passages, complete one of the last word’s miss-
ing letters and answer a comprehension question. An ex-
ample of such a passage is entitled ‘car park’, followed by
‘You have parked your car in the supermarket car park
and just done your weekly food shopping. On your return
to your car you notice a man sat in a nearby car. He is sit-
ting alone and looking out the w-nd-w.’ Hence, for each
item, the third sentence ends with a word that has several
letters missing. Participants are asked to indicate the first
missing letter. For the ‘Car park’ example, the letter ‘i’
would have to be indicated to show that the last word was
‘window’. In order to check that participants correctly
encoded the passage, they had to choose ‘yes’ or ‘no’ as an
answer to a comprehension question, such as ‘Have you
just been to the supermarket?’ which would be correctly
answered with ‘yes’ in the ‘Car park’ example. Participants
are given feedback on the screen about the correctness of
their response to this comprehension question.
For the ‘recognition’ part of the task, participants are
given four sentences, two of which represented ‘targets’ that
capture a paranoid (T−) and a non-paranoid (T+) interpret-
ation of the original passage, respectively. The other two
sentences represent ‘foils’ that contain either paranoid- or
non-paranoid content that is unrelated to the correspond-
ing passage. These foils are used to control for response
bias which refers to the tendency to, for instance, endorse
information that is congruent with a paranoid schema
rather than actually interpreting the specific item in a para-
noid way [17]. For the ‘Car park’ example, the correspond-
ing target paranoid interpretation is ‘The passenger does
not want to sit next to you’ (T−) and the corresponding
non-paranoid interpretation is ‘The passenger wants more
legroom’ (T+). ‘Your friend is ignoring you’ and ‘Your
friend is busy at work’ represent a paranoid foil (F−) and a
non-paranoid foil (F+), respectively. Participants are asked
to rate ‘how similar in meaning from 1 = very different in
meaning to 4 = very similar’, each of the four sentences is to
the corresponding original passage. By comparing partici-
pants’ ratings of each of the four sentences, we can infer
their spontaneous interpretation of the original passage. In-
terpretation bias scores can be calculated as described
above (T+ minus T−) for the screening version of this task.
 Scrambled sentences task (SST) [47, 48]. In this pen-
and-paper task participants are presented with ‘non-
sense’ sentences, each comprising six words and are
asked to select and re-order five of these words to
create a grammatically correct sentence. For example,
‘pleasant to people hostile me are’ could become
‘people are hostile to me’ (paranoid interpretation) or
‘people are pleasant to me’ (non-paranoid interpret-
ation). There are fifteen sentences in total and partici-
pants have 5 min to complete as many as possible.
The order of words selected is indicated by partici-
pants writing the numbers ‘1’ to ‘5’ above the words.
Instructions to participants ask them to ‘choose what-
ever comes to mind first’ and form statements rather
than questions. Before unscrambling the 15 sentences,
participants are asked to memorise a six-digit number
(e.g. 615239) which they are told to keep in mind
while doing the task and which they are asked to
recall after completion of the task. Rude et al. [47]
showed that the addition of this cognitive load makes
the task more sensitive to detecting interpretation
biases possibly because it stops participants suppress-
ing biases. For instance, negative interpretation bias
on the SST only predicted depression if the SST was
performed under cognitive load [47]
Two values are recorded: (a) the total number of
grammatically correct sentences created with a paranoid
meaning is recorded for each participant (including
those using fewer than five words, such as ‘people are
hostile’) and (b) the total number of items attempted
within the available time. From these values a negative
(paranoid) interpretation bias score is calculated as a
proportion: [A/B] × 100. Bias scores, therefore, range
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from 0 to 100, with higher values reflecting bias favour-
ing paranoid interpretations.
 Cognitive Flexibility Scale (CFS) [49]. This self-report
measure consists of 12 items that participants rate
on a 6-point scale ranging from 1 (strongly disagree)
to 6 (strongly agree). It measures the three components
of cognitive flexibility: (a) awareness that in any given
situation there are options and alternatives available,
(b) willingness to be flexible and adapt to the situation
and (c) self-efficacy in being flexible
Psychotic symptoms are measured at baseline using
the PANSS [40] conducted by a trained clinical psych-
ologist. This is a 30-item clinical tool that measures
symptom severity in psychosis. It consists of three sub-
scales with seven items for positive symptoms, seven
items for negative symptoms and 16 items for general
symptoms. Each symptom is rated on a 7- point Likert
scale from 1 (symptom absent) to 7 (symptom extreme),
with a minimum score of 7 and a maximum score of 40
for the PANSS subscales; and a minimum score of 16
and a maximum score of 112 for the general symptoms.
Specifically, severity of paranoid symptoms is assessed
by PANSS item 6 (P6 Suspiciousness/Persecution) which
can be used in isolation to evaluate degree of clinical
paranoia. This item measures unrealistic or exaggerated
ideas of persecution using a 7-point Likert scale where
1 = absent; 2 =minimal, may be at upper extreme of nor-
mal limits; 3 = mildly symptomatic, then incrementally
upwards to 7 = extreme persecutory delusions.
In addition to the PANSS item 6, the following self-report
scales will be used to assess paranoid symptoms: the Para-
noia Scale [50], the Paranoid Thoughts Scale [51] and the
Peters Delusions Inventory (PDI-21) [52]. Although the lat-
ter is not a clinical symptom measure, it includes subscales
reflecting clinically important elements of delusional idea-
tion: degree of delusional conviction, frequency of delu-
sional thoughts and degree of associated distress.
Symptoms of depression/anxiety are assessed using the
Hospital Anxiety and Depression Scale (HADS) [53].
Stress/distress is assessed using three measures:
 Virtual Reality Environment (VRE). Participants wear
a headset through which they view a three-
dimensional social scene populated by neutral
characters (a cafe). Participants spend approximately
4 min in the virtual environment and can move
through the virtual environment by walking and whole
body turning. Visual Analogue Scale (VAS) measures
of state mood assess how anxious, sad, paranoid and
friendly participants feel and are given immediately
before and after experiencing the virtual environment.
Participants also complete the State Social Paranoia
Scale (SSPS) [54]. The 10 items for this measure of
recent paranoid thinking contain both elements of
threat and intention (e.g. ‘Someone had it in for me’,
‘Someone stared at me in order to upset me’, ‘Someone
was trying to isolate me’, ‘Someone was trying to make
me distressed’). Each item is scored on a 5-point scale
(Do not agree – Totally agree). Higher scores indicate
greater levels of persecutory thinking [13, 55]
 Laughter task [56]. Two experimental events are
presented during the testing session. These are (a)
an interruption by a female stooge calling the
experimenter out of the room and (b) following the
exit of the stooge and the experimenter, a 35-s audio
recording of male and female laughter played
outside the room. The recording is played using an
iPad and is identical for each participant. The
laughter was piloted in a sample of five individuals
(without a history of mental illness and with English as
a first language) to ensure that it was audible to those
inside the room without sounding so loud so as to
seem artificial. The aim of the task is to expose
participants to two ‘real-life’ events that are inherently
ambiguous by nature. At the end of the testing session
participants are asked a series of questions to assess
their explanations for these two events. Verbatim
explanations given by individuals for each of the events
are rated for the presence of a paranoid attribution (an
idea of reference or an idea of persecution)
 Visual Analogue Scales. Anxious, sad, paranoid and
friendly state mood will be assessed using a simple
VAS pre and post each training session to determine
the immediate subjective impact on participants of
taking part in the intervention. Furthermore, the
academic literature suggests that state emotion may
influence paranoia-relevant biases [57] and intervention
effects might, therefore, be moderated by emotional
experience during training
Procedures
The assessment procedure is outlined in Fig. 2. The first
contact with participants is during screening, where we
check for participants’ eligibility by assessing the inclu-
sion and exclusion criteria described above. Based on
this screening contact, researchers complete a capacity
assessment to confirm that they perceived participants
to understand and retain information sufficiently to
make an informed choice about taking part in the study.
Following informed consent, baseline assessment (T0)
will be completed prior to randomisation, at the start of
session 1, and will include measures of:
 Sociodemographic information such as age, gender,
ethnicity, IQ [58], educational level, employment
and relational status
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 Paranoid beliefs (SRT, SST and CFS). Twelve SRT
items and their corresponding comprehension
questions are presented at a pace that is determined
by the participant. The order of items is randomised.
Participants then answer similarity ratings questions
entitled by the corresponding 12 SRT items.
Moreover, two sets of 15 scrambled sentences, taken
from Savulich et al. [17], are counterbalanced across
participants, so that half of participants received SST
set 1 while the other half received SST set 2.
Whether or not participants perform the SRT before
the SST, or vice versa, is counterbalanced: half of
participants perform the SRT first, while the other
half performs the SST first, in order to minimise
potential effects that one task might have on the
performance on the other task
 Clinical symptoms assessed using the PANSS,
Paranoia Scale, Paranoid Thoughts Scale, PDI-21
and HADS, as well as the Structured Clinical
Interview for DSM-5 (SCID-5) [59] will be conducted
by a trained Clinical Psychologist (AT) during
baseline assessment
After receiving the intervention (CBM-pa or text-
reading control) interim assessment (Ti1–5) includes at
each time point:
 Paranoid beliefs measured using a total of eight
items of the SRT
 Paranoid symptoms assessed by PANSS item 6
(P6 Suspiciousness/Persecution) only
At week 6, after receiving the intervention, the assess-
ment (T1) includes measures of:
 Paranoid beliefs (SRT, SST and CFS). As for T0, SRT
and SST contain the same number of items (12 and
15, respectively) and are counterbalanced across
participants
 Clinical symptoms (PANSS item 6, Paranoia
Scale, Paranoid Thoughts Scale, PDI-21 and
HADS)
 Vulnerability to stress using the Laughter Task and
VRE in counterbalanced order
Participants will be contacted at 1 and 3 months from
end of the session 6 for follow-up assessments (T2–T3)
which include:
 Paranoid beliefs measured, using a total of 12 items
from the SRT
 Clinical symptoms (PANSS item 6, Paranoia
Scale, Paranoid Thoughts Scale, PDI-21 and
HADS).
Data monitoring
The researchers involved in the study will enter data into
an SPSS spreadsheet. There will be four separate spread-
sheets for each assessment phase (baseline, interim, end
of intervention and follow-ups). The data will be stored
on a locked group drive, only accessible to researchers
in the ‘Emotion and Cognition’ group at IoPPN, King’s
College London.
The separate SPSS spreadsheets will be merged, once
all data have been entered and checked. The randomisa-
tion data and trial data will only be linked once all data
collection is complete. All databases will be organised
according to anonymised participant ID number
(assigned at baseline) which will ensure that the data-
bases are merged correctly.
Risk management
Capacity to consent is assessed via a standard written
protocol approved by the Ethics Committee [43]. The
clinical psychologist will assess and ensure the safety of
participants throughout the course of the study. A Risk
Assessment Form has been developed and adapted from
the protocol used at the Psychological Interventions
Clinic for outpatients with Psychosis (PICuP) in order to
minimise any potential adverse events. The study has
been assessed as low risk, however, the VRE and Laugh-
ter Task could be perceived as mildly stressful for those
experiencing paranoia. To address this, the nature of the
task, including the option to withdraw, will be described
in writing (Information Sheet) and reiterated verbally
immediately prior to the relevant session. Mood state
will be assessed before leaving and at follow-up contact.
Any adverse events and serious adverse events will be
recorded and reported in full in the trial report/journal
paper. Any adverse events, defined as any events that re-
sult in death, serious injury or hospitalisation, which are
considered by the chief investigator or Trial Manage-
ment Group (TMG) to be related to trial procedures in
any way, or are unexpected in that they are not listed in
the trial protocol, will be reported promptly to the spon-
sor and the Ethics Committee.
Analysis
Statistical analysis
Analyses will be conducted using STATA 13 [60]. De-
scriptive statistics will be used to summarise clinical and
demographic characteristics of patients. Feasibility of
trial procedures will be examined using proportions and
95% confidence intervals for assessments of feasibility
and acceptability in terms of recruitment, consent, drop-
out, follow-up and integrity of double blinding.
The variance observed in this sample will be used for
sample size calculation for the future RCT. As recom-
mended by Browne [37] and Lancaster and colleagues
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[39] the 80% upper one-sided confidence limit of the
variance estimate rather than the variance estimate itself
will be used. The final effect size for sample size calcula-
tions will be obtained by dividing the minimum clinically
important difference by this variance estimate. We de-
fine a clinically important difference as a symptom score
drop of ≥20%. To assess efficacy of the intervention
using the SRT [41] a three-factorial within-and-between
group design will be used with a random-effects model
[61]. These analyses will follow the intention-to-treat
principle, with data from all participants who entered
the study included into the analysis. Emphasis will be on
confidence interval of effect sizes estimation rather than
hypothesis testing which allows us to assess the impreci-
sion of the estimates. Rates and characteristics of drop-
out will be explored and where appropriate, statistical
techniques for handling missing data will be used. Fur-
thermore, to address a limitation given the size of the
sample employed, statistical analyses will be corrected
for multiple testing.
Health economic analysis
As this is a feasibility study, a full economic evaluation
is premature as the sample is small and costs are highly
variable in this population which can lead to inaccurate
results. However, piloting of economic outcomes and
service use questionnaires is advisable. To assess the
feasibility and acceptability of economic-related mea-
sures in this population, the Adult Service Use Schedule
(AD-SUS) [62–64], European Quality of Life-5 Dimen-
sions 3 level (EQ-5D-3 L) [63–65] and the 12-item Short
Form Health Survey (SF-12) version 2 [66] will be
piloted. We will not perform an economic evaluation
but will explore completion rates and missing data for
the AD-SUS, EQ-5D-3 L and SF-12. Additionally, we will
explore resources described in the free-text sections of
the AD-SUS to determine if any frequently used
resources have been omitted. The AD-SUS will be used
to measure individual-level resource use. It has been
successfully applied in a range of adult mental health
populations [62–64]. Further, for use in this study, the
AD-SUS has been modified based on clinical expertise,
and our LEAP service user group feedback. The AD-SUS
records all-cause hospital- and community-based health-
and social-care services including the use of psycho-
tropic medication. The AD-SUS will be completed in in-
terviews with participants and collected at baseline, at
the end of intervention (6 weeks after randomisation) and
at 3-month follow-up. The EQ-5D-3 L [65, 67, 68] is a
self-completion instrument used to measure health-
related quality of life. It consists of five domains (mobility,
self-care, usual activities, pain/discomfort and anxiety/de-
pression) and a rating of own health by means of a VAS.
Respondents report difficulties in each area on three levels
(none, some/moderate, extreme). The SF-12 [66] is also a
health-related quality of life measure. It consists of eight
domains (physical functioning, social functioning, physical
role limitations, emotional role limitations, energy, pain,
mental health and general health perceptions). Two sum-
mary scores are produced: the mental health component
score and the physical health component score. Both the
EQ-5D-3 L and the SF-12 will be completed at baseline
and at 3-month follow-up. They can be used to generate
health states, utility values and quality-adjusted life-years
(QALYs) when appropriate.
Qualitative analysis
Data will be transcribed by study researchers for the-
matic analysis. The LEAP group will be involved in iden-
tifying themes and codes, supported by McPin’s previous
similar experience. Data will be analysed using the prin-
ciples of grounded theory and framework analysis [69–
71]. In this approach, categories or themes emerge nat-
urally from the data during an iterative process of coding
and revision that can identify recurrent patterns of
views/experiences.
Discussion
Persecutory delusions are at the severe end of a paranoia
spectrum, associated with poorer health, emotional well-
being and social functioning [2], and for which treat-
ments need to be significantly improved. There is
evidence that persecutory delusions are maintained by
underlying cognitive biases which perpetuate distressing
paranoid beliefs [72], specifically biases in the interpret-
ation of emotional ambiguity [17, 18, 73]. Consequently,
there are calls for new psychological treatments to be
developed which target these maintaining mechanisms
[72]. To date, there has been no intervention that
uniquely targets the biased interpretation of emotional
ambiguity that is known to be associated with clinical
[18] and non-clinical [17] paranoia.
The current study will evaluate CBM-pa which directly
targets biased interpretation of emotional ambiguity
relevant to paranoia. If effective, CBM-pa could offer a
new intervention to complement other psychological
treatments (including CBT) [74]. New targeted interven-
tions are required because CBT effect sizes for delusions
are small to modest [75], a significant proportion of pa-
tients do not respond fully and resource limitations re-
strict availability [76]. This has been recognised by the
advent of the IAPT-SMI (Increasing Access to Psycho-
logical Therapies for Severe Mental Illness) programme.
The development of an evidence base for psychological
treatments is seen as a priority for IAPT- SMI [77] and
the evaluation of CBM-pa could contribute to these de-
velopments, as a potential low-cost, accessible and flex-
ible intervention.
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For more details about the trial, refer to the SPIRIT
Checklist (Additional file 2).
Trial status
Recruitment commenced in May 2016 and will continue
until August 2017.
Additional files
Additional file 1: Examples of CBM-pa and control conditions. Figure
S1a. Instructions for the task are included within the programme and dis-
played before the participant begins. There is no time limit on the instruc-
tions. Figure S1b. A CBM-pa intervention passage. The passage is initially
ambiguous, but the final word solution requires the participant to interpret
in a non-paranoid way. Participants are initially given 20 s to read the
passage, and 20 s to complete the word solution. Figure S1c. The
participant is required to enter the first missing letter of the word, and is
given positive feedback if they do so. Figure S1d. An incorrect response
prompts the participant to try again, and more letters are given to help.
Participants are given 23 s to respond. Figure S1e. The solution is
then shown for 5 s regardless of whether a participant types the letter
correctly or not. Figure S1f. A comprehension question is asked to encour-
age the participant to engage with the meaning of the passage. Participants
are given 20 s to answer. Figure S1g. The figure above is shown when a
participant responds in a non-paranoid way, for a maximum of 20 s. Fig-
ure S1h The figure above is shown when a participant responds in a
paranoid way, for a maximum of 20 s. Figure S1i. A text-reading control
passage. The text reading control programme is presented in an identical
fashion to the CBM-pa. (DOCX 158 kb)
Additional file 2: SPIRIT 2013 Checklist: recommended items to address
in a clinical trial protocol and related documents. (DOC 120 kb)
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